X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Orchid Chemicals - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs ORCHID PHARMA LTD - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

ORCHID PHARMA LTD 
   Change

Orchid Chemicals & Pharmaceuticals Ltd. (Orchid) is today a globally recognized, integrated pharmaceutical company with core competencies in the development and manufacture of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms as well... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD ORCHID PHARMA LTD WYETH LTD/
ORCHID PHARMA LTD
 
P/E (TTM) x 27.7 -0.2 - View Chart
P/BV x 5.3 0.2 3,348.7% View Chart
Dividend Yield % 1.3 0.0 -  

Financials

 WYETH LTD   ORCHID PHARMA LTD
EQUITY SHARE DATA
    WYETH LTD
Mar-13
ORCHID PHARMA LTD
Sep-13
WYETH LTD/
ORCHID PHARMA LTD
5-Yr Chart
Click to enlarge
High Rs1,044194 538.4%   
Low Rs81835 2,337.1%   
Sales per share (Unadj.) Rs298.6276.5 108.0%  
Earnings per share (Unadj.) Rs57.2-79.2 -72.3%  
Cash flow per share (Unadj.) Rs58.4-43.5 -134.4%  
Dividends per share (Unadj.) Rs17.000-  
Dividend yield (eoy) %1.80-  
Book value per share (Unadj.) Rs249.553.9 462.5%  
Shares outstanding (eoy) m22.7270.45 32.2%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x3.10.4 753.1%   
Avg P/E ratio x16.3-1.4 -1,125.4%  
P/CF ratio (eoy) x15.9-2.6 -605.0%  
Price / Book Value ratio x3.72.1 175.8%  
Dividend payout %29.70-   
Avg Mkt Cap Rs m21,1578,067 262.3%   
No. of employees `0000.52.8 17.6%   
Total wages/salary Rs m4002,527 15.8%   
Avg. sales/employee Rs Th13,787.46,956.1 198.2%   
Avg. wages/employee Rs Th813.0902.5 90.1%   
Avg. net profit/employee Rs Th2,643.3-1,993.0 -132.6%   
INCOME DATA
Net Sales Rs m6,78319,477 34.8%  
Other income Rs m353407 86.6%   
Total revenues Rs m7,13619,884 35.9%   
Gross profit Rs m1,6171,103 146.7%  
Depreciation Rs m272,519 1.1%   
Interest Rs m65,227 0.1%   
Profit before tax Rs m1,938-6,236 -31.1%   
Minority Interest Rs m020 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-5511 -1.0%   
Tax Rs m632-125 -505.0%   
Profit after tax Rs m1,301-5,580 -23.3%  
Gross profit margin %23.85.7 421.2%  
Effective tax rate %32.62.0 1,625.0%   
Net profit margin %19.2-28.7 -66.9%  
BALANCE SHEET DATA
Current assets Rs m6,98411,014 63.4%   
Current liabilities Rs m2,05632,060 6.4%   
Net working cap to sales %72.6-108.1 -67.2%  
Current ratio x3.40.3 988.8%  
Inventory Days Days9995 104.6%  
Debtors Days Days2434 71.3%  
Net fixed assets Rs m24429,440 0.8%   
Share capital Rs m227705 32.2%   
"Free" reserves Rs m5,4412,043 266.4%   
Net worth Rs m5,6683,800 149.2%   
Long term debt Rs m259,018 0.3%   
Total assets Rs m7,90146,510 17.0%  
Interest coverage x353.3-0.2 -182,957.3%   
Debt to equity ratio x02.4 0.2%  
Sales to assets ratio x0.90.4 205.0%   
Return on assets %16.5-0.8 -2,174.8%  
Return on equity %22.9-146.9 -15.6%  
Return on capital %34.0-3.7 -911.6%  
Exports to sales %0.237.9 0.6%   
Imports to sales %36.322.6 160.7%   
Exports (fob) Rs m157,378 0.2%   
Imports (cif) Rs m2,4654,406 56.0%   
Fx inflow Rs m157,513 0.2%   
Fx outflow Rs m2,6775,649 47.4%   
Net fx Rs m-2,6621,865 -142.8%   
CASH FLOW
From Operations Rs m9231,682 54.9%  
From Investments Rs m317-9,860 -3.2%  
From Financial Activity Rs m-4816,644 -7.2%  
Net Cashflow Rs m759-1,535 -49.5%  

Share Holding

Indian Promoters % 0.0 32.3 -  
Foreign collaborators % 51.1 0.0 -  
Indian inst/Mut Fund % 11.3 4.6 245.7%  
FIIs % 7.2 3.3 218.2%  
ADR/GDR % 0.0 4.6 -  
Free float % 30.4 55.3 55.0%  
Shareholders   21,978 84,811 25.9%  
Pledged promoter(s) holding % 0.0 54.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   DIVIS LABORATORIES  WOCKHARDT LTD.  AUROBINDO PHARMA  FRESENIUS KABI ONCO.  FDC LTD.  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Marginally Lower; FMCG & IT Stocks Witness Losses(Closing)

After opening the day on a positive note today, Indian share markets witnessed losses thereafter and ended their trading session marginally lower.

Related Views on News

ORCHID PHARMA LTD Announces Quarterly Results (4QFY18); Net Profit Up 50.8% (Quarterly Result Update)

Aug 24, 2018 | Updated on Aug 24, 2018

For the quarter ended March 2018, ORCHID PHARMA LTD has posted a net profit of Rs 924 m (up 50.8% YoY). Sales on the other hand came in at Rs 2 bn (down 24.0% YoY). Read on for a complete analysis of ORCHID PHARMA LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Oh Yes! This is the Best Trading Opportunity in Two Decades(Profit Hunter)

Sep 21, 2018

Getting ready to buy stocks once this correction is over? This private sector bank should be on a profit hunter's radar.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

How To Identify Sachin Tendulkars And Rahul Dravids Of Tomorrow For Your Mutual Fund Portfolio(Outside View)

Sep 19, 2018

PersonalFN explains how to pick 'undiscovered' or lesser-known mutual funds that are capable of generating big gains for you.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS